← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #565 OF 1,000 MOST-CITED

Service reports

FDA cited this observation 33 times across 30 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices33
BY FISCAL YEAR
FY20241
FY20233
FY20226
FY20214
FY20204
FY20194
FY20188
FY20173

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.2× the rate of the average FDA-cited firm (10.0% vs 8.3%), across 30 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Service reports do not include the required information.

Allied Medical LLC · Earth City, Missouri · Devices · 2023-11-08

Service reports do not include the required information.

Wello, Inc. · Addison, Texas · Devices · 2023-06-21

Service reports do not include the required information.

Black Forest Medical North America Inc · Cape Coral, Florida · Devices · 2023-02-15

Service reports do not include the required information.

Fischer ANalysen Instrumente GmbH · Leipzig · Devices · 2022-11-04

Service reports do not include the required information.

Integrity Medical Products Inc · Farmers Branch, Texas · Devices · 2022-09-15

Service reports do not include the required information.

Excite Medical of Tampa Bay LLC · Tampa, Florida · Devices · 2022-08-25

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →